Is IBRX or IKT more undervalued in 2026?

CirclFi compares ImmunityBio, Inc. (IBRX) and Inhibikase Therapeutics, Inc. (IKT) using 13 institutional-grade valuation models. IBRX has a Quality of Company score of 5.9/10 while IKT scores 4.4/10.

Which is a better buy — IBRX or IKT?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do IBRX and IKT valuations compare?

IBRX at $7.72 and IKT at $1.77 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

IBRX vs IKT Valuation Comparison 2026 — Intrinsic Value Analysis

IBRX

Biotechnology

ImmunityBio, Inc.

Quality

5.9

out of 10

Value Trap

LOW

Price

$7.72

Last close

Models

11/13

Active

IKT

Biotechnology

Inhibikase Therapeutics, Inc.

Quality

4.4

out of 10

Value Trap

SAFE

Price

$1.77

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	IBRX Fair Value	IBRX Upside	IKT Fair Value	IKT Upside
Bayesian DCF	Intrinsic	$1.07	-86.1%	$0.68	-61.6%
Earnings Power Value	Intrinsic	$0.54	-92.5%	$0.34	-82.4%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for IBRX vs IKT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IBRX vs IKT — Which Stock Is More Undervalued?

IBRX scores higher with a 5.9/10 quality rating vs IKT's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing ImmunityBio, Inc. (IBRX) and Inhibikase Therapeutics, Inc. (IKT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IBRX currently trades at $7.72 with a QOC of 5.9/10, while IKT trades at $1.77 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).